US Macroplastique trial moves on:
This article was originally published in Clinica
Executive Summary
Uroplasty is pressing ahead with efforts to market in the US its minimally invasive, office-based technology for treating female stress urinary incontinence, after completing the patient-enrolment phase of its FDA-approved clinical trial. The multicentre study is evaluating the Minneapolis, Minnesota firm's urethral bulking agent, Macroplastique.